{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:52:28Z","timestamp":1649076748454},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T00:00:00Z","timestamp":1438041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.diagmicrobio.2015.06.003","type":"journal-article","created":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T19:25:16Z","timestamp":1434223516000},"page":"193-197","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia"],"prefix":"10.1016","volume":"83","author":[{"given":"Darren","family":"Culshaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Lamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min J.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0005","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.01516-13","article-title":"In vitro pharmacodynamics of human simulated ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure","volume":"58","author":"Bhalodi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0010","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1086\/520655","article-title":"Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus","volume":"45","author":"Boucher","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0015","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10096-008-0692-2","article-title":"Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE)","volume":"28","author":"Cunha","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/phar.1220","article-title":"Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"33","author":"Kullar","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0025","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/dkm445","article-title":"Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"61","author":"Moise","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1473-3099(09)70200-2","article-title":"Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions","volume":"9","author":"Moise","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/cir764","article-title":"Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case\u2013control study","volume":"54","author":"Moore","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0045","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1mg\/L: a matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0050","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.coph.2010.06.006","article-title":"Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus","volume":"10","author":"Nannini","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0055","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1086\/504084","article-title":"An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus","volume":"42","author":"Patel","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0070","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/jac\/dkn372","article-title":"Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates","volume":"62","author":"Rehm","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0075","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.amjmed.2007.07.008","article-title":"Cubicin Outcomes Registry and Experience (CORE) methodology","volume":"120","author":"Rolston","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0060","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.50.4.1581-1585.2006","article-title":"Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin","volume":"50","author":"Sakoulas","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0065","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.clinthera.2009.09.012","article-title":"Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience","volume":"31","author":"Sakoulas","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.diagmicrobio.2015.06.003_bb0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10096-010-1128-3","article-title":"Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient\u2014a review of the literature","volume":"30","author":"van Hal","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889315002047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889315002047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T16:57:25Z","timestamp":1537549045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889315002047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0732889315002047"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.06.003","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}